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Abstract The crystal structure of a cyclic form of a mutant of
bovine pancreatic trypsin inhibitor has been solved at 1.0 Aî
resolution. The protein was synthesized by native chemical
ligation and its structure is almost indistinguishable from the
previously described recombinant form of the same mutant;
however, the new loop containing the former termini became
much better ordered. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Native proteins contain only linear polypeptide chains,
although some peptidic antibiotics, defensins [1], plant pro-
tease inhibitors [2] and an antibacterial peptide [3] can be
cyclic. Thus all the protein structures currently represented
in the Protein Data Bank consist of only linear chains con-
taining both amino and carboxy termini, with the exception of
a few nuclear magnetic resonance (NMR) structures of pro-
teins shorter than V70 amino acids [2^6]. However, arti¢-
cially prepared cyclic versions of several proteins have been
reported [7^10]. Such arti¢cial constructs proved to be inter-
esting for studies on the in£uence of the termini on the stabil-
ity and folding pathways. In particular, a cyclic form of bo-
vine pancreatic trypsin inhibitor (cBPTI) was synthesized and
its folding and stability properties were extensively analyzed
[7,11,12]. In addition, the structure of cBPTI was studied by
1H NMR in solution, although no atomic model resulted
from this study that relied on early procedures of two-dimen-
sional (2D) NMR [13].
Several recent developments convinced us that it might now
be worthwhile to apply modern tools of structural biology to
this old problem. While the original technique utilized to pro-
duce cBPTI relied on the treatment of native protein with
water-soluble carbodiimide and resulted in rather low yield
and purity of the product [7], we realized that a simple mod-
i¢cation of the recently described procedure of total chemical
synthesis of BPTI by native chemical ligation [14,15] could
produce large amounts of extremely pure product. While crys-
tal growth of native BPTI is not particularly easy and repro-
ducible [16], it was recently reported that a four-point BPTI
mutant (T11A, P13A, K15R, M52L) produces excellent crys-
tals overnight [17]. The structure of that mutant, solved at
ultrahigh resolution [18], is very similar to that of native
BPTI, indicating that this form of the protein might be opti-
mal for the preparation of cBPTI. Finally, current progress in
collecting di¡raction data at low temperature on synchrotron
sources made it likely that an atomic resolution structure of
cBPTI could be obtained with only a moderate e¡ort.
2. Materials and methods
2.1. Materials
Boc-L-amino acids were purchased from Peptide Institute (Osaka,
Japan). All other chemicals used in peptide syntheses and puri¢ca-
tions, unless noted otherwise, were obtained from the same sources as
previously described [14]. Analytical and preparative reversed-phase
high performance liquid chromatography (HPLC) were performed on
Waters 2690 and Delta Prep 600 systems, respectively, using Vydac
C18 columns. Analysis of crude and puri¢ed peptides by electrospray
ionization mass spectrometry was performed on Micromass ZQ-4000.
Machine-assisted stepwise solid phase peptide synthesis (SPPS) was
done on an Applied Biosystems 433A synthesizer using a custom-
designed chemistry tailored from the in situ neutralization/HBTU
activation protocol for Boc-SPPS [19].
2.2. Chemical synthesis of mutant cBPTI
The procedure for preparation of BPTI by native chemical ligation
[14] has been modi¢ed to yield the cyclic version of the mutant pro-
tein. The chain was assembled starting from Gly37, continuing
through the previous N terminus by addition of the C-terminal
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Fig. 1. Analytical HPLC traces of unfolded and folded cBPTI. Con-
ditions were 15^40% acetonitrile containing 0.1% TFA over 30 min
at a £ow rate of 1 ml/min at 40‡C.
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residues, and ¢nishing the synthesis with Cys38. Synthesis of the
rearranged 58-residue peptide thioester, i.e. (38^58)-(1^37)KCOSR
(R = CH2CO-Leu-OH), was accomplished on Boc-Gly-SCH2CO-
Leu-OCH2-PAM (4-(hydroxymethyl)-phenylacetamidomethyl) resin.
After chain assembly, the peptide was deprotected and cleaved by
HF in the presence of 5% p-cresol at 0‡C for 1 h, then loaded onto
preparative reversed-phase HPLC for puri¢cation. To obtain cBPTI,
100 mg of puri¢ed peptide thioester were dissolved in 16 ml of 0.25 M
phosphate bu¡er, pH 7.5, containing 6 M GuHCl and 1% thiophenol.
The cyclization reaction, i.e. intra-molecular native chemical ligation,
was completed in 3 h. The cBPTI polypeptide was further puri¢ed by
HPLC using a gradient of 15^40% acetonitrile containing 0.1% TFA
over 60 min. The observed mass of the cyclization product is 6453.2
Da, which is in good agreement with the expected value of 6453.5 Da
calculated based on average isotope compositions. It is worth pointing
out that inter-molecular ligation products were not detected under the
conditions used. This is in general agreement with the fact that intra-
molecular chemical reactions are always much faster than their inter-
Fig. 2. Structure of the cyclic form of BPTI. A: Stereo tracing of the CK backbone of the protein. The connection between residues 1 and 58
is marked in red. B: 2Fo3Fc electron density contoured at 1.5c for the peptide bond between Ala58 and Arg1. C: 2Fo3Fc electron density
contoured at 1.5c for the peptide bond between Gly37 and Cys38, the site of chemical ligation in the synthesis of the peptide. Illustrations gen-
erated with Molscript [23], Bobscript [24] and Raster3D [25].
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molecular counterparts, presumably due to increased e¡ective local
concentrations of reactants and/or favorable activation entropy or
enthalpy in the transition state [20].
2.3. Folding and puri¢cation
Folding and disul¢de formation was achieved by dissolving 50 mg
puri¢ed cyclic BPTI polypeptide in 32 ml 6 M GuHCl containing 36
mg cysteine and 7.2 mg cystine, to which 68 ml water containing 840
mg NaHCO3 was added. After gentle stirring overnight at room tem-
perature, the folded product was obtained (Fig. 1). Compared with
the reduced cBPTI, the folded protein eluted earlier on the analytical
HPLC column, which is consistent with burial of hydrophobic resi-
dues during folding. The mass for the folded cBPTI was found to be
6447.3 Da, 6 mass units lower than that of the reduced one, indicative
of the formation of three disul¢de bonds. Interestingly, refolding of
cBPTI was as e⁄cient as the linear counterpart, suggesting that free
termini are not a prerequisite for protein folding initiation. In fact
Goldenberg and Creighton [11] demonstrated that both forms of
BPTI followed an identical folding/unfolding pathway.
2.4. Crystallographic procedures
Crystals of folded cBPTI were grown by the previously described
procedure [17] and were isomorphous with those of the mutant of the
linear protein [18]. X-ray data were collected at 100 K on beamline
X9B, NSLS, Brookhaven National Laboratory, with the ADSC
Quantum4 CCD detector, using a wavelength of 0.92 Aî . Data were
processed using the HKL2000 suite [21], resulting in 32 347 unique
re£ections with the ¢nal R-merge of 7.0% (from the initial 728 960
re£ections). The structure was re¢ned anisotropically using the pro-
gram SHELXL [22], resulting in a model with a root mean square
deviation (r.m.s.d.) of bond lengths and angles of 0.017 Aî and 2.08‡
respectively; R = 11.2%, Rfree = 16.3%. The coordinates of cBPTI have
been submitted to the Protein Data Bank (PDB) with the accession
code 1k6u.
3. Results and discussion
3.1. Stability of cBPTI
Previous studies of cBPTI have shown that the introduction
of a chemical bond between the termini preserves the inhib-
itory function of the protein [7]. It was also reported that the
termini do not play an important role in the early stages of
folding, but there were signi¢cant di¡erences in the stabilities
and rates of interconversions of some of the intermediates
[11]. Studies utilizing 2D 1H NMR showed that only the res-
idues adjacent to the modi¢cation site in cBPTI are perturbed
[13]. In the native structure, a salt bridge between Arg1 and
Ala58 contributes V4 kJ/mol to the protein stability, which is
of the same magnitude as the stabilizing e¡ect of the Arg1^
Ala58 peptide bond. Thus, in the solution structure of cBPTI
the salt bridge and the covalent bond have an almost equiv-
alent e¡ect on the stability of the protein [13]. The crystal
structure of cBPTI reported here is in good agreement with
these data. Superposition of cBPTI and linear BPTI structures
shows a virtually identical main chain and larger deviations of
terminal residues.
3.2. Comparison to BPTI
The structure of cBPTI (Fig. 2A) is extremely similar to
that of the corresponding linear molecule, with the r.m.s.d.
0.1 Aî between the CK coordinates that excluded residues 57,
58 and 1. Both the peptide bond between the former termini
(Fig. 2B) and the bond between Gly37 and Cys38 that had to
be made in order to cyclize the polypeptide (Fig. 2C) are well
ordered. The side chain of Cys38 is observed in a well-con-
served dual conformation, in spite of this residue being in-
volved in the cyclization reaction. The re¢ned occupancies
of the SQ atoms from Cys38 are 0.6/0.4 which are identical
to the occupancies reported for the same crystal form of the
linear protein [18], con¢rming the static disorder of the two
variants of BPTI. The temperature factors of the two SQ
atoms are also the same within experimental error. Since the
chemical bond introduced between Cys38 and Gly37 is the
same as the naturally occurring bond, it does not have an
in£uence on the mobility of the Cys38 side chain. The average
B factor of residue Gly37 is the same as the average B factor
of the Cys38 main chain.
There is a smaller number of disordered side chains in the
Fig. 3. Comparison of the average main-chain temperature factors for cBPTI (blue) with the 1 Aî structure of native BPTI (green) [26] and the
0.86 Aî structure of mutant BPTI (red) [18].
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cBPTI structure, all of them being conserved compared to
the ultrahigh-resolution structure. However, residues Gly56^
Gly57 are in a single, well-de¢ned conformation, unlike the
dual conformations in the 0.86 Aî structure. This is due to the
stabilizing e¡ect of the nearby Arg1^Ala58 peptide bond. In
the linear form of BPTI the dual conformation of residues
Gly56^Gly57 is synchronized with the double conformation
Lys26 side chain and the main chain of Leu29 [18]. In cBPTI
Lys26 is slightly farther from both the ordered residues
Gly56^Gly57 (more than 3.5 Aî ) and Leu29 (more than 5.1
Aî ). The sulfate ions are also well conserved between cBPTI
and the 0.86 Aî resolution structure. Arg20 has an ion-binding
site, harboring a sulfate or a phosphate ion, depending on
which ion was present in the crystallization condition.
3.3. Flexibility of the termini
The temperature factors of cBPTI are very similar to those
of the linear native protein except for the termini, which are
subject to much lower thermal motions than those reported in
the high-resolution structures of either native or mutant BPTI
(Fig. 3). This linked-terminal region with reduced thermal
motion becomes a new £exible loop in cBPTI, with temper-
ature factors comparable to the other loops, such as loop 13^
17 and 25^28.
A superposition of the main chain atoms in three high-res-
olution crystal structures shows the range of di¡erent confor-
mations adopted for residues 56^58 and 1^3 (Fig. 4). The N-
terminal residues Arg1^Asp3 are fairly well conserved in these
structures, N and CK of Arg1 showing the largest deviations:
1.7 and 1.1 Aî relative to the same atoms in cBPTI. The C-
terminal residues from Gly56 show much larger deviations. In
the 0.86 Aî crystal structure, residues 56^58 deviate by an
overall 3.5 Aî and in the 1 Aî native structure Gly57 has an
overall deviation of 4.5 Aî and Ala58 of 11.0 Aî . This is also
apparent from the temperature factors of these residues (Fig.
3), with a much higher £exibility of the C-terminus than the
N-terminus.
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